PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis
Fang Wang,1,* Feng-Hua Wang,2,3,* Kaiyu Sun,4,* Chang Jiang,2,5 Sui Peng,6 Li-Xia Xu,1 Ming Kuang,7 Gui-Fang Guo,2,5,8 Shu-Ling Chen9 1Department of Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, People's Republic of China; 2State Key Labor...
Guardado en:
Autores principales: | Wang F (Autor), Wang FH (Autor), Sun K (Autor), Jiang C (Autor), Peng S (Autor), Xu LX (Autor), Kuang M (Autor), Guo GF (Autor), Chen SL (Autor) |
---|---|
Formato: | Libro |
Publicado: |
Dove Medical Press,
2022-10-01T00:00:00Z.
|
Materias: | |
Acceso en línea: | Connect to this object online. |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Endoscopic Ultrasound-Guided Biliary Drainage for Unresectable Hilar Malignant Biliary Obstruction
por: Yousuke Nakai, et al.
Publicado: (2019) -
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
por: Cheng Huang, et al.
Publicado: (2021) -
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Ruijia Chen, et al.
Publicado: (2022) -
Changing Trends in Biliary Stenting for Unresectable Malignant Perihilar Obstructions
por: Lubna Kamani, et al.
Publicado: (2020) -
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Zhuo-miao Ye, et al.
Publicado: (2023)